PEOPLE ON THE MOVE
Mission Therapeutics
Drug developed Mission Therapeutics has appointed the former CEO of OSI Pharmaceuticals, Colin Goddard, to the company’s board.
“We are privileged to have Dr Goddard join our board at this exciting phase of Mission’s growth and development,” said Chairman Michael Moore.
“Dr Goddard has more than 25 years of outstanding leadership experience in the US biopharmaceutical industry and will add a complementary strategic dimension to our board. We look forward to benefiting from his corporate vision, as we continue to transition our business into a clinical stage organisation.”
Goddard joined OSI as a research scientist in 1989 and became CEO in 1998. He was involved in the approval of OSI’s treatment for non-small cell lung cancer and pancreatic cancer, Tarceva (erlotinib) and in several acquisitions and divestitures, raising over $1.5bn in capital. OSI was acquired by Astellas Pharma in 2010 for $4bn.